T. Rowe Price Investment Management
BDTX icon

T. Rowe Price Investment Management’s Black Diamond Therapeutics BDTX Stock Holding History

T. Rowe Price Investment Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.5M Sell
10,563,103
-43,496
-0.4% -$103K 0.02% 455
2025
Q4 		$25.8M Sell
10,606,599
-137,508
-1% -$487K 0.02% 452
2025
Q3 		$40.7M Buy
10,744,107
+231,973
+2% +$679K 0.02% 414
2025
Q2 		$26.1M Buy
10,512,134
+112,893
+1% +$218K 0.02% 470
2025
Q1 		$16.1M Sell
10,399,241
-67,480
-0.6% -$141K 0.01% 532
2024
Q4 		$22.4M Sell
10,466,721
-267,668
-2% -$767K 0.01% 503
2024
Q3 		$46.7M Buy
10,734,389
+74,659
+0.7% +$406K 0.03% 414
2024
Q2 		$49.7M Buy
10,659,730
+3,934,365
+59% +$21.1M 0.03% 389
2024
Q1 		$34.1M Buy
6,725,365
+2,797,486
+71% +$11.3M 0.02% 450
2023
Q4 		$11M Buy
3,927,879
+1,774,291
+82% +$4.16M 0.01% 509
2023
Q3 		$6.18M Buy
+2,153,588
New +$7.93M ﹤0.01% 537

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

T. Rowe Price Investment Management's BDTX Position: Q1 2026 in Review

T. Rowe Price Investment Management reduced its Black Diamond Therapeutics (BDTX) stake by 0.41% in Q1 2026, selling an estimated $103K and leaving 10,563,103 shares worth $22.5M. The position accounts for 0.02% of the portfolio, ranked #455.

T. Rowe Price Investment Management first reported a position in BDTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $49.7M in Q2 2024. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • T. Rowe Price Investment Management held 10,563,103 shares of Black Diamond Therapeutics worth $22.5M as of Q1 2026.
  • T. Rowe Price Investment Management sold 43,496 Black Diamond Therapeutics shares in Q1 2026, an estimated $103K.
  • Black Diamond Therapeutics made up 0.02% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #455 holding.
  • T. Rowe Price Investment Management first reported a position in Black Diamond Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • T. Rowe Price Investment Management's Black Diamond Therapeutics position peaked at $49.7M in Q2 2024.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.